
CLAIMS

1. A crystalline form of a compound represented by Structural Formula I:



(I),

wherein the crystalline form is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 4.4°, 19.9°, 21.3° and 22.0°.

2. The crystalline form of claim 1, wherein the crystalline form is characterized by X-ray powder diffraction peaks at 2θ angles of 4.4°, 19.9°, 21.3° and 22.0°.

3. The crystalline form of claim 2, wherein the crystalline form is characterized by X-ray powder diffraction peaks at 2θ angles of 4.4°, 19.9°, 20.3°, 21.3°, 22.0°, 23.5° and 25.0°.

4. The crystalline form of claim 3, wherein the crystalline form is characterized by X-ray powder diffraction peaks at 2θ angles of 4.4°, 13.1°, 15.8°, 18.2°, 19.9°, 20.3°, 21.3°, 22.0°, 23.5°, 23.7°, 25.0°, 27.0°, 28.3° and 28.5°.

5. The crystalline form of claim 1, wherein the crystalline form is characterized by X-ray powder diffraction peaks at 2θ angles of 4.4°, 12.4°, 13.1°, 14.5°, 14.7°, 15.8°, 16.9°, 17.5°, 18.2°, 19.9°, 20.3°, 21.3°, 22.0°, 23.1°, 23.5°, 23.7°, 23.9°, 25.0°, 25.3°, 25.6°, 27.0°, 27.3°, 28.3°, 28.5°, 31.4°, 34.8°, and 37.2°.

6. The crystalline form of claim 1, wherein the crystalline form is further characterized

by a differential scanning calorimetry thermogram comprising an endothermic peak at 179°C.

7. The crystalline form of Claim 1, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with that depicted in FIG. 1A.

8. Use of a crystalline form of any one of Claims 1-7, in the manufacture of a medicament for treating a disorder associated with CRM1 activity.

9. The use of claim 8, wherein the use is for wound healing.

10. The use of claim 8, wherein the disorder is a proliferative disorder, cancer, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, an allergic disorder, or a respiratory disorder.

11. The use of claim 10, wherein the disorder is cancer.

12. The use according to claim 11, wherein the cancer is a leukemia, a myeloma or a lymphoma.

13. The use according to claim 11, wherein the cancer is multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, macroglobulinemia, lung cancer, liposarcoma, alveolar soft part sarcoma, Ewing's sarcoma, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer, pancreatic cancer, salivary gland cancer, melanoma, glioblastoma, malignant thymoma, myelodysplastic syndrome, a myeloproliferative disorder, B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia,

acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) or chronic lymphocytic leukemia.

14. The use according to claim 13, wherein the cancer is multiple myeloma.

15. The use according to claim 13, wherein the cancer is diffuse large B-cell lymphoma.

16. The use according to claim 11, wherein the cancer is selected from liposarcoma, endometrial cancer, or glioblastoma.

17. The use according to claim 11, wherein the cancer is endometrial cancer.

18. The use according to claim 11, wherein the cancer is lung cancer.

19. The use according to claim 11, wherein the cancer is colorectal cancer.

20. The use according to claim 11, wherein the cancer is a myeloproliferative disorder.

21. The use according to any one of claims 8-20, wherein the medicament is to be administered orally.

22. The use according to any one of claims 8-21, wherein the medicament is to be administered together with an additional therapeutic agent.

23. The use according to claim 22, wherein the additional therapeutic agent is selected from dexamethasone, bortezomib or a combination thereof.

24. The use according to claim 22, wherein the second therapeutic agent is bortezomib.

25. The use according to claim 22, wherein the additional therapeutic agent is dexamethasone.

26. The use according to claim 22, wherein the additional therapeutic agents are bortezomib and dexamethasone.

27. A crystalline form of any one of Claims 1-7, for use in therapy.